Formica et al. meta-analyzed patients with BRAF-mutant stage 2 and 3 CC but included publications that used divergent statistical outcome measures [43,44], contained a subset of patients with rectal cancers which follow a different treatment algorithm altogether in the early-stage setting [45], and included patients with non-V600 BRAF mutations, which are known to be associated with differential prognosis and response to MAPK-targeted therapy [5,44,46]. The gene discussed is BRAF; the disease is rectal cancer.